trending Market Intelligence /marketintelligence/en/news-insights/trending/qcig4rcdys06xtte7_qi4q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

TapImmune raises $3.1M via stock purchase agreement

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


TapImmune raises $3.1M via stock purchase agreement

TapImmune Inc. raised gross proceeds of about $3.1 million under a stock purchase agreement.

Under the agreement, an existing accredited investor bought 1,300,000 common shares at $2.40 each in a private placement.

Additionally, TapImmune raised gross proceeds of about $2 million under a warrant exercise agreement.

Under the agreement, certain existing institutional investors bought 782,506 shares at a reduced exercised price, and for cash immediately.

Jacksonville, Fla.-based TapImmune develops immunotherapeutics and vaccines for cancer and metastatic disease.